Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCG-Refractory Bladder Cancer”

73 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 73 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03022825
What this trial is testing

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
ImmunityBio, Inc. 190
Testing effectiveness (Phase 2)UnknownNCT05957757
What this trial is testing

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20
Not applicableAvailableNCT06443944
What this trial is testing

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Who this might be right for
Non-Muscle Invasive Bladder CancerUrothelial CarcinomaUrologic Cancer+1 more
CG Oncology, Inc.
Early research (Phase 1)WithdrawnNCT04109092
What this trial is testing

Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Who this might be right for
Urinary Bladder Neoplasms
Eisai Inc.
Large-scale testing (Phase 3)Study completedNCT00006034
What this trial is testing

Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
Intracel
Not applicableEnded earlyNCT04142359
What this trial is testing

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Who this might be right for
Pharmacokinetics
Altor BioScience 1
Testing effectiveness (Phase 2)Study completedNCT02365818
What this trial is testing

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

Who this might be right for
Bladder Cancer
CG Oncology, Inc. 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Large-scale testing (Phase 3)Active Not RecruitingNCT05704244
What this trial is testing

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder Cancer
Ferring Pharmaceuticals 25
Testing effectiveness (Phase 2)Looking for participantsNCT07283835
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd. 16
Large-scale testing (Phase 3)Study completedNCT02773849
What this trial is testing

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Superficial Bladder Cancer
Ferring Pharmaceuticals 157
Testing effectiveness (Phase 2)Study completedNCT01687244
What this trial is testing

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
FKD Therapies Oy 40
Testing effectiveness (Phase 2)Ended earlyNCT03719300
What this trial is testing

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Who this might be right for
Non-muscle Invasive Bladder Cancer (NMIBC)
Anchiano Therapeutics Israel Ltd. 32
Large-scale testing (Phase 3)Not Yet RecruitingNCT07424287
What this trial is testing

Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Who this might be right for
NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 236
Early research (Phase 1)Study completedNCT02808143
What this trial is testing

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaStage 0a Bladder Urothelial CarcinomaStage 0is Bladder Urothelial Carcinoma+1 more
Northwestern University 9
Testing effectiveness (Phase 2)Looking for participantsNCT06388720
What this trial is testing

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Who this might be right for
Bladder Cancer
National Cancer Center, Korea 82
Testing effectiveness (Phase 2)Ended earlyNCT02901548
What this trial is testing

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Who this might be right for
Carcinoma in Situ of BladderBladder Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Testing effectiveness (Phase 2)Looking for participantsNCT03945162
What this trial is testing

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc. 90
Testing effectiveness (Phase 2)WithdrawnNCT04040725
What this trial is testing

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Who this might be right for
Bladder Cancer
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT06972615
What this trial is testing

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Who this might be right for
Non Muscle Invasive Bladder Cancer
BLATAM 37
Load More Results